• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2011年生物分析近期问题白皮书以及审计和检查的监管结果

2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections.

作者信息

Garofolo Fabio, Rocci Mario L, Dumont Isabelle, Martinez Suzanne, Lowes Steve, Woolf Eric, van Amsterdam Peter, Bansal Surendra, Barra Ariadna Cristina Gomes, Bauer Ronald, Booth Brian P, Carrasco-Triguero Montserrat, DeSilva Binodh, Dunn John, Gallicano Keith, Gouty Dominique, Ho Stacy, Hucker Richard, Jemal Mohammed, Katori Noriko, Le Blaye Olivier, Lee Jean, Li Wenkui, Michael Steve, Nehls Corey, Nicholson Robert, Ormsby Eric, Tang Daniel, Viswanathan C T, Weiner Russell, Young Graeme

机构信息

Algorithme Pharma Inc., Laval (Montreal) Quebec, H7V 4B3, Canada.

出版信息

Bioanalysis. 2011 Sep;3(18):2081-96. doi: 10.4155/bio.11.192.

DOI:10.4155/bio.11.192
PMID:21942519
Abstract

The 5th Workshop on Recent Issues in Bioanalysis (WRIB) was organized by the Calibration and Validation Group as a 2-day full immersion workshop for pharmaceutical companies, CROs and regulatory agencies to discuss, review, share perspectives, provide potential solutions and agree upon a consistent approach to recent issues in the bioanalysis of both small and large molecules. High quality, better compliance to regulations and scientific excellence are the foundation of this workshop. As in the previous editions of this significant event, recommendations were made and a consensus was reached among panelists and attendees, including industry leaders and regulatory experts representing the global bioanalytical community, on many 'hot' topics in bioanalysis. This 2011 White Paper is based on the conclusions from this workshop, and aims to provide a practical reference guide on those topics.

摘要

第五届生物分析近期问题研讨会(WRIB)由校准与验证小组组织,是一场为期两天的沉浸式研讨会,面向制药公司、合同研究组织(CRO)和监管机构,旨在讨论、审查、分享观点、提供潜在解决方案,并就小分子和大分子生物分析近期问题达成一致方法。高质量、更好的法规遵从性和科学卓越性是本次研讨会的基础。与这一重要活动的往届会议一样,在包括代表全球生物分析界的行业领袖和监管专家在内的小组成员和与会者之间,就生物分析中的许多“热点”话题提出了建议并达成了共识。这份2011年白皮书基于本次研讨会的结论,旨在为这些话题提供实用的参考指南。

相似文献

1
2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections.2011年生物分析近期问题白皮书以及审计和检查的监管结果
Bioanalysis. 2011 Sep;3(18):2081-96. doi: 10.4155/bio.11.192.
2
2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines.2012年关于生物分析近期问题及多项指南比对的白皮书。
Bioanalysis. 2012 Sep;4(18):2213-26. doi: 10.4155/bio.12.205.
3
2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop.2009年第三届校准与验证小组研讨会关于规范生物分析近期问题的白皮书。
Bioanalysis. 2010 Jan;2(1):53-68. doi: 10.4155/bio.09.134.
4
2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance.2010年关于规范生物分析近期问题及生物分析指南全球协调的白皮书。
Bioanalysis. 2010 Dec;2(12):1945-60. doi: 10.4155/bio.10.164.
5
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1--small molecules by LCMS).
Bioanalysis. 2014;6(22):3039-49. doi: 10.4155/bio.14.265.
6
2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs ( - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).2022 年生物分析近期问题白皮书:ICH M10 BMV 指南和全球协调;混合测定法;寡核苷酸和 ADC;非液相和稀有基质;监管意见(-关于质谱、色谱和样品制备的建议,新型技术,新型模式和新的挑战,ICH M10 BMV 指南和全球协调-监管机构对监管生物分析/ BMV、生物标志物/ CDx/ BAV、免疫原性、基因和细胞治疗以及疫苗的输入)。
Bioanalysis. 2023 Aug;15(16):955-1016. doi: 10.4155/bio-2023-0167. Epub 2023 Aug 31.
7
2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody - Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).2023 年生物分析新问题白皮书:氘代药物;LNP;肿瘤/FFPE 活检;靶向蛋白质组学;小分子共价抑制剂;手性生物分析;远程监管评估;样品核对/监管链-关于质谱、色谱、样品制备最新进展、挑战和解决方案的建议,以及 BMV/监管生物分析-监管机构对监管生物分析/BMV、生物标志物/IVD/CDx/BAV、免疫原性、基因和细胞治疗以及疫苗的投入。
Bioanalysis. 2024;16(9):307-364. doi: 10.1080/17576180.2024.2347153. Epub 2024 May 27.
8
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input).2014年生物分析近期问题白皮书:全面深入了解生物分析(第2部分 - 混合配体结合分析/液相色谱 - 质谱联用、电子实验室笔记本及监管机构的投入)
Bioanalysis. 2014;6(23):3237-49. doi: 10.4155/bio.14.279.
9
2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome ( - Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in Small Molecules, Peptides and Oligos).2020 年生物分析近期问题白皮书:混合测定法的生物变异度、声质谱、高分辨质谱、数据完整性、内源性化合物、微采样和微生物组(-关于行业/监管机构对 LCMS 生物疗法的生物变异度的共识建议、混合测定法中的高级应用、质谱法规挑战、小分子、肽和寡核苷酸的创新)。
Bioanalysis. 2021 Feb;13(4):203-238. doi: 10.4155/bio-2020-0324. Epub 2021 Jan 20.
10
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity).
Bioanalysis. 2014;6(24):3355-68. doi: 10.4155/bio.14.283.

引用本文的文献

1
2024 White Paper on Recent Issues in Bioanalysis: Three Way-Cross Validation; Urine Clinical Analysis; Automated Methods; Regulatory Queries on Plasma Protein Binding; Automated Biospecimen Management; ELN Migration; Ultra-Sensitivity Mass Spectrometry ( - Recommendations on Advanced Strategies for Mass Spectrometry Assays, Chromatography, Sample Preparation and BMV/Regulated Bioanalysis - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV).2024年生物分析近期问题白皮书:三方交叉验证;尿液临床分析;自动化方法;血浆蛋白结合的监管问询;自动化生物样本管理;电子实验室笔记本迁移;超灵敏质谱法(- 质谱分析、色谱法、样品制备及生物等效性/法规生物分析的先进策略建议 - 监管机构对法规生物分析/生物等效性的意见)
Bioanalysis. 2025 Mar;17(5):299-337. doi: 10.1080/17576180.2025.2450194. Epub 2025 Jan 25.
2
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).2024年生物分析近期问题白皮书:超越ADA/NAb的免疫原性评估演变;规范的基因组/NGS检测;超敏反应;最小降噪;假阳性范围;现代化疫苗方法;NAb/TAb相关性——基因治疗、细胞治疗、疫苗分子检测和免疫原性的先进策略建议;生物治疗药物免疫原性评估与临床相关性——监管机构对生物治疗药物、基因、细胞和疫苗治疗的免疫原性/技术的意见)
Bioanalysis. 2025 Feb;17(3):105-149. doi: 10.1080/17576180.2024.2439229. Epub 2025 Jan 25.
3
2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA ( - Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) - Regulatory Agencies' Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation).2024年生物分析近期问题白皮书:美国实验室开发检测(LDT)和欧盟体外诊断医疗器械法规(IVDR)的影响;用于高参数流式细胞术的人工智能/机器学习;欧林克技术的兴起;腺相关病毒(AAV)基因疗法的伴随诊断(CDx);多平台整合生物分析;超灵敏抗药物抗体/中和抗体配体结合分析(LBA)(-关于生物标志物、体外诊断/伴随诊断检测(BAV)、基于细胞的检测(CBA)和配体结合分析(LBA)的先进策略建议-监管机构对生物标志物、体外诊断/伴随诊断及生物标志物检测验证的意见)
Bioanalysis. 2025 Feb;17(4):211-248. doi: 10.1080/17576180.2024.2442218. Epub 2025 Jan 25.
4
2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody - Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).2023 年生物分析新问题白皮书:氘代药物;LNP;肿瘤/FFPE 活检;靶向蛋白质组学;小分子共价抑制剂;手性生物分析;远程监管评估;样品核对/监管链-关于质谱、色谱、样品制备最新进展、挑战和解决方案的建议,以及 BMV/监管生物分析-监管机构对监管生物分析/BMV、生物标志物/IVD/CDx/BAV、免疫原性、基因和细胞治疗以及疫苗的投入。
Bioanalysis. 2024;16(9):307-364. doi: 10.1080/17576180.2024.2347153. Epub 2024 May 27.
5
2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( - Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies).2023 年生物分析最新问题白皮书:欧盟 2017/746 法规实施/影响,IVD/CDx/CLIA 批准的检测,高维细胞计数,多重检测技术,LBA 组织分析,疫苗研究终点,基于细胞的生物标志物分析,细胞疗法和疫苗(- 生物标志物、IVD、CDx、基于细胞、流式细胞术、配体结合和酶检测的开发和验证建议;先进的关键试剂策略)。
Bioanalysis. 2024;16(8):179-220. doi: 10.1080/17576180.2024.2340961. Epub 2024 May 22.
6
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization).2023 年生物分析新问题白皮书:ADA 分析的 ISR、dPCR 对 qPCR 的兴起、疫苗分析的国际参考标准、抗 AAV TAb 给药后评估、NanoString 验证、作为金标准的 ELISpot - 基因治疗、细胞治疗、疫苗免疫原性和技术建议;生物治疗药物免疫原性和风险评估;ADA/NAb 分析/报告的协调统一)。
Bioanalysis. 2024 Apr;16(7):77-119. doi: 10.4155/bio-2024-0024. Epub 2024 Feb 22.
7
Stability of Drugs, Drug Candidates, and Metabolites in Blood and Plasma.药物、候选药物及代谢物在血液和血浆中的稳定性
Curr Protoc Pharmacol. 2016 Dec 13;75:7.6.1-7.6.12. doi: 10.1002/cpph.16.
8
Utilizing Internal Standard Responses to Assess Risk on Reporting Bioanalytical Results from Hemolyzed Samples.利用内标响应评估溶血样本生物分析结果报告中的风险。
AAPS J. 2015 Sep;17(5):1168-76. doi: 10.1208/s12248-015-9783-z. Epub 2015 May 15.
9
Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teams.小分子特异性运行验收、特异性分析操作及色谱运行质量评估:全球生物分析联盟协调团队关于最佳实践和协调的建议
AAPS J. 2014 Sep;16(5):885-93. doi: 10.1208/s12248-014-9633-4. Epub 2014 Jun 25.
10
Large molecule specific assay operation: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team.大分子特异性检测操作:全球生物分析联盟协调团队关于最佳实践与协调的建议
AAPS J. 2014 Jan;16(1):83-8. doi: 10.1208/s12248-013-9542-y. Epub 2013 Nov 16.